16:38 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

bluebird gets accelerated assessment ahead of MAA for β-thalassemia gene therapy

bluebird bio Inc. (NASDAQ:BLUE) said EMA’s CHMP granted LentiGlobin BB305 accelerated assessment to treat patients with transfusion-dependent β-thalassemia. The company plans to submit an MAA for LentiGlobin BB305 this half. LentiGlobin BB305, which comprises autologous CD34+...
22:11 , Jul 23, 2018 |  BC Extra  |  Financial News

bluebird, Catalent propose $400M follow-ons

Cell therapy company bluebird bio Inc. (NASDAQ:BLUE) and drug delivery play Catalent Inc. (NYSE:CTLT) each proposed to raise $400 million follow-ons late Monday. bluebird's follow-on will be underwritten by Goldman Sachs, BofA Merrill Lynch, J.P. Morgan,...
18:26 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....
23:28 , Jun 15, 2018 |  BC Extra  |  Clinical News

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
19:01 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

bluebird bio starts Phase III for LentiGlobin BB305 gene therapy

bluebird bio Inc. (NASDAQ:BLUE) began the U.S. Phase III Northstar-3 (HGB-212) trial to evaluate LentiGlobin BB305 gene therapy to treat 15 patients with transfusion-dependent beta thalassemia of the beta-0/beta-0 genotype. The single-arm, open-label study's primary endpoint...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
06:30 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

bluebird reports updated LentiGlobin data

bluebird bio Inc. (NASDAQ:BLUE) said treatment with the company's LentiGlobin BB305 gene therapy using a modified protocol led to improved vector copy numbers (VCNs) in 2 patients receiving the therapy in the open-label, U.S. Phase...
22:28 , Nov 1, 2017 |  BC Extra  |  Clinical News

bluebird reports updated LentiGlobin data, 3Q17 earnings

bluebird bio Inc. (NASDAQ:BLUE) said treatment with the company's LentiGlobin BB305 gene therapy using a modified protocol led to improved vector copy numbers (VCNs) in two patients receiving the therapy in the Phase I HGB-206...
21:27 , Oct 26, 2017 |  BC Innovations  |  Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...